Literature DB >> 10969830

The c-Jun amino-terminal kinase pathway is preferentially activated by interleukin-1 and controls apoptosis in differentiating pancreatic beta-cells.

A Ammendrup1, A Maillard, K Nielsen, N Aabenhus Andersen, P Serup, O Dragsbaek Madsen, T Mandrup-Poulsen, C Bonny.   

Abstract

To characterize the differentiation events that selectively target insulin-producing cells to interleukin (IL)-1beta-induced apoptosis, we studied IL-1beta signaling via mitogen-activated protein kinase (MAPK) and stress-activated protein kinase in 2 pancreatic endocrine cell lines. We studied the glucagon-secreting AN-glu cell line and the insulin and the islet amyloid polypeptide-producing beta-cell line (AN-ins cells), which is derived by stable transfection of AN-glu cells with the transcription factor pancreatic duodenal homeobox factor-1. AN-ins cells were more sensitive to the cytotoxic action of IL-1beta. This increased sensitivity was not associated with a more pronounced IL-l-induced nitric oxide production in AN-ins cells, but it correlated with a more marked activation of the 3 MAPKs extracellular signal-regulated kinases (ERKs)-1/2, c-Jun NH2-terminal kinase (JNK), and p38 MAPK (p38). This led to increased phosphorylation of the transcription factors c-Jun, Elk-1, and ATF2 and of heat shock protein 25. Inhibition of ERK-1/2 and p38 did not prevent but aggravated IL-1beta-induced cell death. In contrast, inhibition of JNK by transfection with the dominant negative inhibitor of the JNK-binding domain prevented apoptosis in both cell types. Cell death could be elicited by overexpressing the catalytic domain of MAPK kinase kinase 1, a specific activator of JNK and nuclear factor-kappaB, which does not recruit ERK-1/2 or p38. Coactivation of ERK-1/2 with JNK did not prevent apoptosis. In conclusion, increased MAPK signaling in response to IL-1beta may represent a novel molecular marker of beta-cell differentiation. JNK inhibition represents an effective means of preventing IL-1beta-activated beta-cell destruction.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10969830     DOI: 10.2337/diabetes.49.9.1468

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  70 in total

Review 1.  Blockade of interleukin 1 in type 1 diabetes mellitus.

Authors:  Thomas Mandrup-Poulsen; Linda Pickersgill; Marc Yves Donath
Journal:  Nat Rev Endocrinol       Date:  2010-03       Impact factor: 43.330

2.  c-Jun NH2-terminal kinase mediates interleukin-1beta-induced inhibition of lacrimal gland secretion.

Authors:  Driss Zoukhri; Elizabeth Macari; Sun H Choi; Claire L Kublin
Journal:  J Neurochem       Date:  2005-11-21       Impact factor: 5.372

3.  Activation of c-Jun NH2-terminal kinase (JNK) pathway during islet transplantation and prevention of islet graft loss by intraportal injection of JNK inhibitor.

Authors:  H Noguchi; Y Nakai; M Ueda; Y Masui; S Futaki; N Kobayashi; S Hayashi; S Matsumoto
Journal:  Diabetologia       Date:  2007-01-16       Impact factor: 10.122

4.  Apoptosis Repressor With Caspase Recruitment Domain Ameliorates Amyloid-Induced β-Cell Apoptosis and JNK Pathway Activation.

Authors:  Andrew T Templin; Tanya Samarasekera; Daniel T Meier; Meghan F Hogan; Mahnaz Mellati; Michael T Crow; Richard N Kitsis; Sakeneh Zraika; Rebecca L Hull; Steven E Kahn
Journal:  Diabetes       Date:  2017-07-20       Impact factor: 9.461

5.  Suppressor of cytokine signalling (SOCS)-3 protects beta cells against IL-1beta-mediated toxicity through inhibition of multiple nuclear factor-kappaB-regulated proapoptotic pathways.

Authors:  A E Karlsen; P E Heding; H Frobøse; S G Rønn; M Kruhøffer; T F Orntoft; M Darville; D L Eizirik; F Pociot; J Nerup; T Mandrup-Poulsen; N Billestrup
Journal:  Diabetologia       Date:  2004-12-02       Impact factor: 10.122

6.  Oxidative stress, ER stress, and the JNK pathway in type 2 diabetes.

Authors:  Hideaki Kaneto; Taka-Aki Matsuoka; Yoshihisa Nakatani; Dan Kawamori; Takeshi Miyatsuka; Munehide Matsuhisa; Yoshimitsu Yamasaki
Journal:  J Mol Med (Berl)       Date:  2005-03-10       Impact factor: 4.599

7.  12-Lipoxygenase Products Reduce Insulin Secretion and {beta}-Cell Viability in Human Islets.

Authors:  K Ma; C S Nunemaker; R Wu; S K Chakrabarti; D A Taylor-Fishwick; J L Nadler
Journal:  J Clin Endocrinol Metab       Date:  2010-01-20       Impact factor: 5.958

8.  c-Jun N-terminal kinase 1 is deleterious to the function and survival of murine pancreatic islets.

Authors:  J L Varona-Santos; A Pileggi; R D Molano; N Y Sanabria; A Ijaz; M Atsushi; H Ichii; R L Pastori; L Inverardi; C Ricordi; A Fornoni
Journal:  Diabetologia       Date:  2008-10-14       Impact factor: 10.122

9.  A combined "omics" approach identifies N-Myc interactor as a novel cytokine-induced regulator of IRE1 protein and c-Jun N-terminal kinase in pancreatic beta cells.

Authors:  Flora Brozzi; Sarah Gerlo; Fabio Arturo Grieco; Tarlliza Romanna Nardelli; Sam Lievens; Conny Gysemans; Lorella Marselli; Piero Marchetti; Chantal Mathieu; Jan Tavernier; Décio L Eizirik
Journal:  J Biol Chem       Date:  2014-07-25       Impact factor: 5.157

10.  Protein expression changes in a cell system of beta-cell maturation reflect an acquired sensitivity to IL-1beta.

Authors:  K Nielsen; T Sparre; M R Larsen; M Nielsen; S J Fey; P Mose Larsen; P Roepstorff; J Nerup; A E Karlsen
Journal:  Diabetologia       Date:  2003-12-03       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.